Premium
Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996
Author(s) -
BERTHJONES J.,
VOORHEES J.J.
Publication year - 1996
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1996.d01-1061.x
Subject(s) - psoriasis , medicine , microemulsion , dermatology , chemistry , pulmonary surfactant , biochemistry
Cyclosporin A (CyA) has been registered in over 124 countries world-wide and is used by more than 50,000 psoriasis patients per year. Human studies using oral CyA (Sandimmun®) therapy for psoriasis have been in progress for nearly 13 years, and have confirmed the clinical efficacy of CyA in this indication. Guidelines have been developed and adopted for the safe use of CyA in psoriasis, ̂ '̂ and the relative safety of up to 2 years of therapy has been established, provided that the guidelines are observed. However, there is concern regarding the long-term safety of CyA treatment of psoriasis as experience is still limited. Careful monitoring of all CyA-treated patients is therefore mandatory. This meeting was convened to re-examine the current recommendations for the use of CyA in psoriasis, in the light of developments since the last consensus conference in 1992;^ namely, the growing understanding of psoriasis, changes in clinical practice (including the use of intermittent short-course therapy), and increased clinical experience with the new microemulsion formulation of CyA (Sandimmun Neoral®). The principal outcome of the meeting was the creation of an updated set of recommendations for the use of the CyA microemulsion in adult psoriatic patients; these recommendations are presented below. It should be noted, however, that the recommendations are intended only as guidelines and it is assumed that clinical judgement will always be exercised.